ArticleClinical cancer research : an official journal of the American Association for Cancer Research2015

A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma.

Thomas J Galloway et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.